|
gptkbp:instance_of
|
gptkb:skincare_product
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:activities
|
CFTR modulator
|
|
gptkbp:approves
|
gptkb:Cystic_fibrosis
|
|
gptkbp:availability
|
Available in pharmacies
|
|
gptkbp:class
|
gptkb:Cystic_fibrosis_transmembrane_conductance_regulator_(CFTR)_modulators
|
|
gptkbp:clinical_trial
|
gptkb:EVOLVE_study
Phase 3
Long-term treatment
EXPAND study
|
|
gptkbp:contraindication
|
Hypersensitivity to components
|
|
gptkbp:dosage_form
|
gptkb:Tezacaftor/_Ivacaftor
Two tablets daily
|
|
gptkbp:formulation
|
gptkb:tablet
|
|
gptkbp:frequency
|
Twice daily
|
|
gptkbp:has_programs
|
Patient assistance programs
|
|
gptkbp:healthcare
|
February 2018
Important for prescribing
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Symdeko
|
|
gptkbp:indication
|
Cystic fibrosis with specific mutations
|
|
gptkbp:ingredients
|
gptkb:Ivacaftor
gptkb:Tezacaftor
|
|
gptkbp:interacts_with
|
CY P3 A inducers
CY P3 A inhibitors
|
|
gptkbp:invention
|
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:is_monitored_by
|
Liver function tests
Pulmonary function tests
|
|
gptkbp:label
|
Patient information leaflet
|
|
gptkbp:manager
|
Oral
|
|
gptkbp:manufacturer
|
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:packaging
|
Blister pack
|
|
gptkbp:population
|
Aged 12 years and older
|
|
gptkbp:price
|
High cost
|
|
gptkbp:provides_information_on
|
Recommended in treatment guidelines
|
|
gptkbp:regulatory_compliance
|
Prescription only
Approved by EMA
Approved by FDA
Approved by Health Canada
|
|
gptkbp:research_areas
|
gptkb:dictionary
|
|
gptkbp:research_focus
|
Cystic fibrosis treatment advancements
|
|
gptkbp:safety_features
|
Generally well tolerated
|
|
gptkbp:scholarships
|
Support groups available
|
|
gptkbp:side_effect
|
gptkb:Nausea
Diarrhea
Fatigue
Headache
Elevated liver enzymes
Gastrointestinal symptoms
Upper respiratory tract infection
Respiratory symptoms
|
|
gptkbp:storage
|
Room temperature
|
|
gptkbp:target_audience
|
Patients with cystic fibrosis
|
|
gptkbp:treatment
|
Chronic disease management
|
|
gptkbp:type_of_care
|
Important for efficacy
|